ANCA-Associated Vasculitis Treatment in India
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is ANCA-Associated Vasculitis?
ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases that cause inflammation and damage to small blood vessels. The main forms are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The inflammation can affect multiple organs, particularly the kidneys, lungs, upper airways, skin, nerves and, in some patients, the eyes or gastrointestinal system. AAV is often associated with antibodies called antineutrophil cytoplasmic antibodies (ANCA), although not every patient with AAV is ANCA-positive.
What is the Importance of Timely Treatment?
Early diagnosis and treatment are important because active vasculitis can rapidly damage organs, particularly the kidneys and lungs. Severe disease can lead to rapidly progressive kidney failure, pulmonary haemorrhage or other life-threatening complications. Treatment aims to control inflammation, achieve remission and prevent permanent organ damage and relapses. Current guidelines recommend prompt induction therapy for organ- or life-threatening disease.
What are the Common Symptoms of ANCA-Associated Vasculitis?
- Persistent fatigue and weakness
- Fever or unexplained weight loss
- Joint and muscle pain
- Skin rashes or purpura, particularly on the legs
- Sinusitis, nasal congestion or recurrent nose problems
- Nosebleeds or nasal crusting
- Cough or shortness of breath
- Coughing up blood in severe lung involvement
- Blood or protein in the urine
- Swelling of the legs or feet
- Reduced kidney function
- Numbness, tingling or weakness due to nerve involvement
- Eye redness, pain or vision changes
- Gastrointestinal pain or other organ-specific symptoms
Causes and Risk Factors of ANCA-Associated Vasculitis
Causes
- The exact cause of ANCA-associated vasculitis is not fully understood. It is believed to result from an abnormal immune response in which activated immune cells and, in many patients, ANCA antibodies contribute to inflammation and injury of small blood vessels.
- Genetic susceptibility and environmental or infectious triggers may contribute to disease development.
Risk Factors
- Genetic susceptibility
- Family history of autoimmune or vasculitic disease
- Exposure to certain environmental or occupational factors
- Some infections or medications, particularly in selected forms of ANCA-positive vasculitis
- Increasing age for certain AVV subtypes
Latest Research and Technologies in the Treatment of ANCA-Associated Vasculitis in India
- Treatment of AAV is evolving toward individualised, steroid-sparing and relapse-aware approaches. Lower-dose glucocorticoid regimens and the complement inhibitor avacopan have expanded steroid-sparing strategies for selected patients. Plasma exchange may also be considered in specific patients with severe kidney involvement or other high-risk presentations. Research is also investigating biomarkers, ANCA characteristics, complement pathways and immune-cell mechanisms to better predict disease activity and relapse. Advanced kidney assessment, high-resolution chest imaging, bronchoscopy when indicated, and kidney biopsy can help determine the extent of organ involvement and guide treatment.
Treatment options for ANCA-Associated Vasculitis
Plasmapheresis : Plasma exchange may be considered for selected patients with severe kidney disease or specific high-risk presentations, after assessing potential benefits and risks.
Cost Start From 450Explore Options
- Clinical assessment:
- Medical and Physical Evaluation: Review a detailed medical and medication history and perform a physical examination to identify systemic and organ-specific manifestations. Assessment may include symptoms and signs involving the kidneys, lungs, nerves, skin, eyes and ENT system, helping determine the pattern and severity of disease.
- Kidney and Laboratory Assessment: Assess kidney function using serum creatinine and estimated GFR, along with urinalysis to detect blood or protein in the urine. Complete blood count, inflammatory markers, liver function tests and other organ-function tests may also be performed when clinically indicated.
- ANCA Testing: Blood testing for antineutrophil cytoplasmic antibodies (ANCA), can support the diagnosis and provide information about the AAV subtype. However, interpret ANCA results alongside clinical findings because a positive result does not confirm AAV, and some patients with AAV may be ANCA-negative.
- Tissue Biopsy: Kidney or other tissue biopsy may be recommended when the diagnosis remains uncertain or when confirmation and assessment of organ damage are important. In suspected kidney involvement, a kidney biopsy can help identify active vasculitic inflammation, chronic scarring and the extent and pattern of kidney injury.
- Imaging Tests:
- Chest X-ray: May identify lung infiltrates, nodules or other pulmonary abnormalities.
- High-resolution chest CT: Provides detailed assessment of pulmonary nodules, infiltrates, haemorrhage, or interstitial changes.
- CT of the Sinuses: May be used in GPA when persistent upper-airway or sinus involvement is suspected.
- Kidney Ultrasound: Helps assess kidney size and exclude structural causes of kidney dysfunction.
- MRI: May be used when neurological, orbital or other organ involvement requires detailed imaging.
- Echocardiography: Consider when cardiac involvement or pulmonary hypertension is suspected.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support ANCA-Associated Vasculitis patients in India. These services include:
- Physiotherapy: Helps maintain muscle strength, mobility, balance and endurance in patients affected by weakness, nerve involvement or prolonged illness.
- Occupational Therapy: Supports independence with daily activities when fatigue, weakness, neuropathy or joint problems affect function.
- Respiratory Rehabilitation: Selected patients with significant lung involvement may benefit from breathing exercises, pulmonary rehabilitation and monitored physical activity.
- Neurological Rehabilitation: Patients with peripheral nerve involvement may require gait training, balance exercises and targeted rehabilitation.
- Medicines for ANCA-associated vasculitis aim to suppress abnormal immune activity, induce remission and prevent relapse. Selected patients may receive avacopan as a steroid-sparing treatment. Maintenance therapy may involve rituximab or other immunosuppressive medicines, depending on disease type and severity. Doctors may prescribe additional medicines to prevent infection, control blood pressure, manage kidney complications, protect bones, or address other treatment-related risks. Medication selection and dosing require close specialist monitoring because immunosuppressive therapy can increase the risk of infections and other adverse effects.
Instantly Connect with our Specialists
Hospitals for ANCA-Associated Vasculitis in India
Max Super Specialty Hospital, Vaishali
Ghaziabad, India
- Max Super Speciality Hospital, Vaishali, Ghaziabad, is a leading multi-speciality hospital with 387+ beds and 37+ clinical specialities, offering advanced care in Cardiology, Neuro Sciences, Oncology, Orthopaedics, Transplants, Gastroenterology, and Reconstructive Surgery.
- Supported by 389+ doctors and 1038+ trained staff, the hospital combines state-of-the-art technology, including robotic surgery and advanced imaging systems, with compassionate, patient-centred care.
- Accredited by NABH and NABL, Max Vaishali is a trusted destination for both domestic and international patients seeking high-quality, integrated medical services.
Batra Hospital
Delhi, India
- More than 35 years of trusted healthcare service
- Multi-specialty tertiary care with over 30 departments
- Comprehensive preventive, diagnostic, and therapeutic care under one roof
- International patient coordination team for seamless overseas care
Marengo Asia Hospitals, Gurugram
Gurgaon, India
- Marengo Asia Hospitals, Gurugram, is a 250-bed multi-speciality tertiary care hospital, formerly known as W Pratiksha Hospital.
- A major medical centre for Delhi NCR and North India, it is situated on Golf Course Extension Road, Sector 56, Gurugram.
- The hospital's NABH and NABL accreditation ensures compliance with international standards for patient care, safety, and quality.
- Provides extensive medical care in more than 21 specialities, including as women's health, neurology, orthopaedics, cardiology, and cancer.
- Advanced robotic-assisted spine surgery tools and neuro-monitoring technology are available at the Marengo Asia International Institute of Neuro & Spine (MAIINS), a Centre of Excellence in Neurosciences.
- Equipped with cutting-edge equipment, such as automated labs, sophisticated imaging, and contemporary operating rooms.
- Features specialised ICUs, NICUs, and modular OTs built for complex and minimally invasive procedures.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose India for ANCA-Associated Vasculitis Treatment?
- Multidisciplinary Specialist Care: Patients can access rheumatologists, nephrologists, pulmonologists, neurologists and other specialists depending on the organs involved.
- Advanced Diagnostic Facilities: Major centres may provide ANCA testing, kidney biopsy, advanced imaging, pulmonary evaluation and comprehensive laboratory monitoring.
- Modern Immunosuppressive Treatment: Specialised centres may offer steroid-sparing approaches and other treatments according to clinical indications.
- Comprehensive Kidney and Organ Care: Hospitals with nephrology and critical-care services can manage severe kidney disease, pulmonary complications and other organ-threatening manifestations.
- Rehabilitation and International Patient Support: Rehabilitation, nutritional counselling, follow-up care and international-patient coordination can be integrated into the treatment pathway.
Frequently Asked Questions
Recovery varies by AAV type, inflammation severity, organs affected, and response to treatment. Active disease may improve over weeks to months, but long-term maintenance treatment and monitoring are often required because relapses can occur.
Many patients can walk normally, particularly when the disease does not significantly affect the nerves, muscles or joints. Peripheral neuropathy, muscle weakness, joint inflammation or prolonged illness may affect mobility and may require physiotherapy.
Major Indian centres may provide ANCA testing, kidney biopsy, advanced CT and MRI, pulmonary investigations, intensive monitoring and modern immunosuppressive treatments for appropriately selected patients.
Many major Indian hospitals have international-patient departments that can assist with medical records, specialist consultations, treatment coordination, travel arrangements, accommodation and follow-up care.
Consider a centre with experience in systemic autoimmune diseases and access to rheumatology, nephrology, pulmonology, pathology, radiology and critical-care services. For kidney involvement, experience in vasculitis-related kidney disease and kidney biopsy is particularly important.
No single success rate applies to all patients with ANCA-associated vasculitis. Outcomes depend on the AAV subtype, disease severity, organs affected, extent of permanent damage, response to treatment and occurrence of relapses. Early treatment can help control active inflammation and reduce the risk of irreversible organ damage.
Rheumatologists, nephrologists and other specialists in specialised centres manage ANCA-associated vasculitis as part of multidisciplinary autoimmune and systemic inflammatory disease care. Patients should consider a centre with experience managing the affected organs.
Treatment risks depend on the medicines used and the patient's overall health. Immunosuppressive treatments can increase the risk of infections and may cause blood-count abnormalities, liver problems, gastrointestinal effects or other medicine-specific complications. Untreated active vasculitis can also cause serious organ damage.
Persistent symptoms such as unexplained blood or protein in the urine, coughing up blood, shortness of breath, severe weakness, purpuric skin lesions or rapidly worsening neurological symptoms require prompt medical evaluation. Coughing up significant blood, severe breathing difficulty or other signs of organ-threatening disease require urgent medical attention.
ANCA-associated vasculitis does not typically cause structural physical deformities. However, severe or prolonged inflammation can cause permanent kidney damage, nerve injury, lung damage or other functional limitations in some patients.
Yes. Fatigue, pain, nerve problems, kidney or lung complications, treatment side effects and the need for long-term monitoring can affect work, mobility, daily activities and emotional well-being. Rehabilitation and appropriate supportive care can help patients maintain independence and function.
Yes. Untreated active AAV can cause progressive inflammation and permanent damage to organs such as the kidneys, lungs, nerves, eyes and other tissues. Severe cases may result in kidney failure, pulmonary haemorrhage or other life-threatening complications.
There is no established method to prevent most cases of ANCA-associated vasculitis because its exact cause is not fully understood. However, when clinically appropriate, avoiding unnecessary exposure to known medication triggers, attending regular follow-up, and recognising early symptoms may help reduce complications or detect disease activity sooner.
AAV can affect people of different ages and backgrounds, but the frequency and clinical pattern vary among its subtypes. GPA, MPA and EGPA have different demographic and clinical characteristics. Certain genetic, environmental and medication-related factors may contribute to susceptibility, but most patients do not have a single identifiable cause.